PI3K mutations (especially on the PI3K catalytic subunit alpha PIK3CA) are reported in approximately 7–12% of CRC patients and may lead to upfront EGFR resistance [100,101,102,103,104,105]. This evidence concerns the gene EGFR and colorectal carcinoma.